✦ LIBER ✦

Interferon and nucleoside analog combination therapy for hepatitis B

✍ Scribed by Masahito Minami; Takayuki Katayama; Rei Sendo; Takeshi Okanoue; Toshikazu Yoshikawa

Book ID: 107648958
Publisher: Springer Japan
Year: 2010
Tongue: English
Weight: 158 KB
Volume: 3
Category: Article
ISSN: 1865-7257
DOI: 10.1007/s12328-010-0135-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefits and risks of nucleoside analog

Benefits and risks of nucleoside analog therapy for hepatitis B

✍ Jules L. Dienstag 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Five oral agents have been approved for the treatment of chronic hepatitis B, ranging in virological potency, clinical efficacy, barrier to resistance, and side-effect profile. The degree of histological, biochemical, and serological improvement with therapy generally corresponds to the degree of su

Interferon-ribavirin combination therapy

Interferon-ribavirin combination therapy for chronic hepatitis C

✍ Solko W. Schalm; J. T. Brouwer; L. Chemello; A. Alberti; A. Bellobuono; G. Ideo; 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 466 KB

Combination therapy for chronic hepatiti

Combination therapy for chronic hepatitis B

✍ R J Fontana; A S Lok 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

ing Phase I and Phase II clinical trials. Other forms of experimental treatment that are being examined in in vitro and Currently, interferon alfa is the only approved treatment animal models include antisense oligonucleotides and supfor chronic hepatitis B virus (HBV) infection. A 3-to 6pressive HB

Benefits and risks of interferon therapy

Benefits and risks of interferon therapy for hepatitis B

✍ Robert Perrillo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B

Efficacy of hepatitis B vaccination and

Efficacy of hepatitis B vaccination and interferon-α-2b combination therapy versus interferon-α-2b monotherapy in children with chronic hepatitis B

✍ MEHMET HELVACI; ASLI KIZILGUNESLER; ERHUN KASIRGA; EBRU OZBAL; MUGE KUZU; GULBEN 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Benefits and risks of combination therap

Benefits and risks of combination therapy for hepatitis B

✍ Norah A. Terrault 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay or prevent the emergence of drug-resistant mutants. Because drug-resistant mutants are archived and may limit future therapeutic options, prevention is important for long-